Taiwan- and US-based biopharmaceutical company Foresee Pharmaceuticals has appointed Brian J. Groch as its Chief Commercial Officer (CCO) to lead the global commercial launch strategy for FP-001 42 mg, the company’s investigational six-month, ready-to-use subcutaneous long-acting injectable of leuprolide mesylate for the treatment of central precocious puberty (CPP). His appointment became effective on July 1, 2026.
Groch brings more than three decades of experience in the pharmaceutical industry, having held senior leadership positions at Remi Therapeutics, Shield Therapeutics, Veru, and Horizon Therapeutics. Earlier in his career, he served as Director of Health Policy and Regional Sales at Novartis and spent more than 13 years at Merck leading large-scale commercial and marketing programmes.
“Brian will lead Foresee in building a commercial team to launch the FP-001 for the treatment of CPP patients in the US, Taiwan, and potentially other selected countries,” said Dr. Ben Chien, chairman and chief executive officer of Foresee Pharmaceuticals.
Central precocious puberty is a condition caused by the premature activation of the pituitary-gonadal axis, resulting in early puberty. If left untreated, the condition can lead to accelerated bone maturation, reduced final adult height, and significant psychosocial challenges. The current standard of care involves gonadotropin-releasing hormone (GnRH) agonists to suppress pubertal progression.
FP-001 42 mg is a sustained-release, ready-to-use subcutaneous formulation of leuprolide mesylate designed to provide continuous suppression of gonadotropin secretion for six months following a single injection. The investigational therapy aims to offer a less-frequent and more convenient dosing option compared with existing treatments.
Foresee is advancing its global regulatory strategy for the CPP program. The company plans to submit a New Drug Application (NDA) for FP-001 to the US Food and Drug Administration (FDA) in the second half of 2026. Marketing authorization applications are also scheduled for submission to health agencies in Taiwan and other strategic markets between late 2026 and the first half of 2027.
In parallel, Foresee is conducting pre-NDA meetings and engaging with regulatory agencies to facilitate a streamlined review process.
